Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815426 | 0.91 | MEN1 (0.46) | MEN1KMT2AEPHX2TSHRMAPK1 | |
| SCHEMBL21876953 | 0.91 | MEN1 (0.46) | MEN1KMT2AEPHX2TSHRMAPK1 | |
| SCHEMBL1986730 | 0.91 | MEN1 (0.46) | MEN1KMT2AEPHX2TSHRMAPK1 | |
| SCHEMBL7715014 | 0.91 | MEN1 (0.46) | MEN1KMT2AEPHX2TSHRMAPK1 | |
| Ethylene Glycol SCHEMBL27778535 | 0.89 | MEN1 (0.44) | MEN1KMT2AEPHX2TSHRMAPK1 | |
| Succinic Acid SCHEMBL28041968 | 0.87 | TSHR (0.46) | MEN1KMT2ATSHRMAPK1LMNA | |
| Succinic Acid SCHEMBL27911601 | 0.87 | TSHR (0.46) | MEN1KMT2ATSHRMAPK1LMNA | |
| SCHEMBL127836 | 0.83 | LMNA (0.45) | TSHRMAPK1LMNAADRA2AADRA1A | |
| SCHEMBL21876951 | 0.83 | MEN1 (0.55) | MEN1KMT2AEPHX2TSHRMAPK1 | |
| SCHEMBL21055107 | 0.83 | MEN1 (0.55) | MEN1KMT2AEPHX2TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304187-A1 | EMU Oil In Combination With Other Active Ingredients For Treating Skin Imperfections | DESAI, KETAN | 2017-10-26 | — | — | US | claimed |
| US-20260041663-A1 | PREVENTION OF ROSACEA INFLAMMATION | UNIV CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025096719-A1 | BIOACTIVE WALNUT PEPTIDES AND COMPOSITIONS FOR TOPICAL TREATMENT OF SKIN | L'OREAL (FR) | 2025-05-08 | — | — | WO | disclosed |
| US-20250134794-A1 | BIOACTIVE WALNUT PEPTIDES AND COMPOSITIONS FOR TOPICAL TREATMENT OF SKIN | L'OREAL (FR) | 2025-05-01 | — | — | US | disclosed |
| US-12285404-B2 | Prevention of rosacea inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-29 | — | — | US | disclosed |
| US-12221463-B2 | Method of promoting wound healing by inhibiting CCR3 | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-02-11 | — | — | US | disclosed |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | Ansella Therapeutics, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4464307-A1 | COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME | MPLUS COSMETICS S.R.L. (IT) | 2024-11-20 | — | — | EP | disclosed |
| US-20240374498-A1 | COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME | MPLUS COSMETICS S.R.L. (IT) | 2024-11-14 | — | — | US | disclosed |
| US-20030134760-A1 | Clear conditioning detersive compositions and methods for making the same | CHEMSIL SILICONES, INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030134780-A1 | Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof | PROCYTE CORPORATION | 2003-07-17 | — | — | US | disclosed |
| WO-2003047543-A1 | METHODS FOR THE TREATMENT OF HYPERPIGMENTATION OF SKIN | PROCYTE CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20030095990-A1 | Microemulsion facial washes comprising specific oils | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030082129-A1 | Hair and skin care compositions containing siloxane-based polyamide copolymers | DOW CORNING CORPORATION | 2003-05-01 | — | — | US | disclosed |
| WO-2003030860-A1 | SKIN CARE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND RETINOL, RETINOL DERIVATIVES, OR A MIXTURE THEREOF | PROCYTE CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20030039668-A1 | Trans dermal skin care | NEO TECH DEVELOPMENT COMPANY, L.L.C. | 2003-02-27 | — | — | US | disclosed |
| WO-2003013447-A2 | HAIR AND SKIN CARE COMPOSITIONS CONTAINING SILOXANE-BASED POLYAMIDE COPOLYMERS | DOW CORNING CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002102327-A1 | MICROEMULSION FACIAL WASHES COMPRISING SPECIFIC OILS | UNILEVER PLC (GB) | 2002-12-27 | — | — | WO | disclosed |
| US-6338855-B1 | DISPOSABLE CLEANING SHEETS WITH FROTHS AND SURFACTANTS | THE PROCTER & GAMBLE COMPANY | 2002-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | LIPA, COL2A1, COL1A1 | MEN1 1247/4885KMT2A 4646/4885EPHX2 324/4885 |
| US-20030082129-A1 | Hair and skin care compositions containing siloxane-based polyamide copolymers | CUTA, POLR1C, KRT18 | MEN1 2257/4885KMT2A 650/4885EPHX2 2842/4885 |
| US-20030095990-A1 | Microemulsion facial washes comprising specific oils | MGLL, SQLE, LIPA | MEN1 1441/4885KMT2A 3451/4885EPHX2 425/4885 |
| US-20030134760-A1 | Clear conditioning detersive compositions and methods for making the same | ASH2L, CD47, THOC2 | MEN1 1630/4885KMT2A 90/4885EPHX2 364/4885 |
| US-20260041663-A1 | PREVENTION OF ROSACEA INFLAMMATION | CPA3, CTSD, TPSD1 | MEN1 2286/4885KMT2A 2566/4885EPHX2 1158/4885 |
| US-20030134780-A1 | Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof | RBP1, RBP4, CRABP2 | MEN1 3470/4885KMT2A 3675/4885EPHX2 1244/4885 |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | LIPA, COL2A1, COL1A1 | MEN1 1247/4885KMT2A 4646/4885EPHX2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.